MXPA04001509A - Calcium phosphate particles as mucosal adjuvants. - Google Patents

Calcium phosphate particles as mucosal adjuvants.

Info

Publication number
MXPA04001509A
MXPA04001509A MXPA04001509A MXPA04001509A MXPA04001509A MX PA04001509 A MXPA04001509 A MX PA04001509A MX PA04001509 A MXPA04001509 A MX PA04001509A MX PA04001509 A MXPA04001509 A MX PA04001509A MX PA04001509 A MXPA04001509 A MX PA04001509A
Authority
MX
Mexico
Prior art keywords
mucosal
calcium phosphate
methods
compositions
particles
Prior art date
Application number
MXPA04001509A
Other languages
Spanish (es)
Inventor
S Pratt Steve
Original Assignee
Biosante Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosante Pharmaceuticals Inc filed Critical Biosante Pharmaceuticals Inc
Publication of MXPA04001509A publication Critical patent/MXPA04001509A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to mucosal immune protection, mucosal vaccine delivery, and mucosal drug delivery. Novel calcium phosphate core particles, particularly nanoparticles are used as vaccine adjuvants and compositions for inducing protective mucosal immunity. Methods of inducing an immune response to an antigen by devivering the antigen to a mucosal surface using the particles of this invention are also useful for delivering compositions, such as a pharmacologically active agent, to the mucosal surfaces of a patient in need thereof, to methods of delivering such compositions, and to methods of making such particles.
MXPA04001509A 2001-08-17 2002-08-12 Calcium phosphate particles as mucosal adjuvants. MXPA04001509A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/932,538 US20020068090A1 (en) 1999-02-03 2001-08-17 Calcium phosphate particles as mucosal adjuvants
PCT/US2002/025526 WO2003051394A2 (en) 2001-08-17 2002-08-12 Calcium phosphate particles as mucosal adjuvants

Publications (1)

Publication Number Publication Date
MXPA04001509A true MXPA04001509A (en) 2004-06-03

Family

ID=25462469

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001509A MXPA04001509A (en) 2001-08-17 2002-08-12 Calcium phosphate particles as mucosal adjuvants.

Country Status (7)

Country Link
US (1) US20020068090A1 (en)
EP (1) EP1418939A2 (en)
AU (1) AU2002364932A1 (en)
CA (1) CA2456830A1 (en)
IL (1) IL160447A0 (en)
MX (1) MXPA04001509A (en)
WO (1) WO2003051394A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6355271B1 (en) * 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
DK2116257T3 (en) 2000-08-09 2013-02-04 Alk Abello As Parenteral vaccine formulations and applications thereof
JP2002063917A (en) * 2000-08-18 2002-02-28 Sony Corp Electrochemical device and its usage
US20060062855A1 (en) * 2001-02-27 2006-03-23 Bell Steve J D Therapeutic calcium phosphate particles for use in inhibiting expression of a gene
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
CA2555921A1 (en) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
EP1811941A4 (en) * 2004-11-01 2008-09-10 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
DK1951299T3 (en) 2005-11-04 2012-04-02 Novartis Vaccines & Diagnostic Influenza vaccines containing combinations of particulate adjuvants and immune enhancers
EP2061433B1 (en) * 2006-09-08 2011-02-16 Johns Hopkins University Compositions for enhancing transport through mucus
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
CN101971030A (en) 2007-12-24 2011-02-09 诺华有限公司 Assays for adsorbed influenza vaccines
CA2760945A1 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP3808339A1 (en) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
US11110064B2 (en) * 2018-12-16 2021-09-07 SRM Institute of Science and Technology Gel formulation for treating diabetic foot ulcer infections
WO2022031594A1 (en) * 2020-08-06 2022-02-10 Dianomi Therapeutics, Inc. Compositions and methods for vaccine delivery
CN114181102B (en) * 2021-11-10 2023-06-23 深圳市检验检疫科学研究院 Hexaresorcinol hapten, artificial antigen, antibody and synthesis method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU407324B2 (en) * 1962-05-01 1970-10-28 Smith, Kline & French Laboratories Powdered silicone products and processes
US4070454A (en) * 1973-05-04 1978-01-24 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
FR2227861B1 (en) * 1973-05-04 1976-07-02 Anvar
FR2522269A1 (en) * 1982-02-26 1983-09-02 Pasteur Institut ANTI-TUMOR AGENTS, SUCH AS DAUNORUBICIN, WITH IMPROVED EFFECTIVENESS, THEIR PRODUCTION AND METHOD FOR INCREASING THE EFFECTIVENESS OF ANTI-TUMOR AGENTS
FR2577048B1 (en) * 1985-02-05 1988-05-06 Pasteur Institut REAGENT FOR THE HEMAGGLUTINATION DETERMINATION OF ANTIBODIES AGAINST BACTERIAL TOXINS, METHOD OF PREPARATION AND ITS APPLICATION
IL88961A (en) * 1988-01-29 1992-07-15 Basf Ag Stable mixtures containing oxidation-sensitive compounds
NO168615C (en) * 1989-10-17 1992-03-11 Datalab Oy PROCEDURE AND DEVICE FOR THE IDENTIFICATION OF A COIN
US5469599A (en) * 1993-10-27 1995-11-28 Wurdack; Roy A. Slide
DE4444052A1 (en) * 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmaceutical, oral preparation
US8333996B2 (en) * 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US5648097A (en) * 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
AU6946198A (en) * 1997-04-01 1998-10-22 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microspheres
US6355271B1 (en) * 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use

Also Published As

Publication number Publication date
WO2003051394A3 (en) 2003-12-24
WO2003051394A2 (en) 2003-06-26
US20020068090A1 (en) 2002-06-06
AU2002364932A8 (en) 2003-06-30
EP1418939A2 (en) 2004-05-19
AU2002364932A1 (en) 2003-06-30
IL160447A0 (en) 2004-07-25
CA2456830A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
MXPA04001509A (en) Calcium phosphate particles as mucosal adjuvants.
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
HUP0303720A2 (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
MY129263A (en) Vaccine composition
NZ506603A (en) Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester
WO2006122223A3 (en) Strategies for delivery of active agents using micelles and particles
MXPA03007837A (en) Compositions for delivering bisphosphonates.
AU2001295673A1 (en) Vaccine composition
WO2003061578A3 (en) Compositions for treatment or prevention of bioterrorism
MXPA04004567A (en) Phenoxy amine compounds and compositions for delivering active agents.
GB0109297D0 (en) Vaccine
CA2477260A1 (en) Site specific delivery of co-administered drugs via inhalation
EP1471936A4 (en) Hiv vaccine and method of use
AU2003212170A8 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
WO2004024067A3 (en) Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
AU6721801A (en) The use of plant oil-bodies in vaccine delivery systems
SE0200657D0 (en) Novel Formulation
GB9906695D0 (en) Vaccine composition
EP1303300A4 (en) Compositions and methods for treatment of candidiasis
ATE420658T1 (en) IMIDAZOQUINOLINAMINE AS ADJUVANTS FOR HIV DNA VACCINES
NZ593200A (en) Peptide adjuvants
MY127452A (en) Vaccines.
ATE334658T1 (en) MEDICINAL PRODUCTS FOR ADMINISTRATION TO MUCOUS MEASURES
EA200870361A1 (en) INTRANASAL OR INHALATION INTRODUCTION BY VIROS